ישראל - עברית - Ministry of Health

csl behring ltd., israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg/ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - prophylaxis of rh (d) immunisation in rh (d)-negative women: anti-d immune globulin is administered for the prevention of rh (d) immunization if it has been demonstrated or if it is suspected that fetal erythrocytes have entered the circulation of the mother. treatment is not necessary when it is assured that the child or the father are rh (d)- negative. criteria for a rhesus-incompatible pregnancy and the administration of anti-d immune globulin are : a) the mother is rh (d) -negative b) the child is either rh (d)-positive rh (d)weak - positive or its rhesus type is not known. routine antepartum prophylaxis : to prevent rh (d) immunisation due to spontaneous fetomaternal haemorrhage (fmh) during the last trimester of pregnancy. postpartum prophylaxis to prevent rh (d) immunisation of the rh (d)-negative mother following delivery of a rh (d)-positive child. complications of pregnancy: interventions during pregnancy such as invasive prenatal diagnosis (e.g. amniocentesis chorionic villus sampling fetal blood s

ישראל - עברית - Ministry of Health

sam-on ltd - nicotinic acid; pepsin; sodium glycerophosphate - טיפות - pepsin 0.6 %w/v; nicotinic acid 0.2 %w/v; sodium glycerophosphate 0.8 %w/v - pepsin and acid preparations - pepsin and acid preparations - treatment of constipation and flatulence.

ישראל - עברית - Ministry of Health

novartis israel ltd - zoledronic acid - תמיסה לאינפוזיה - zoledronic acid 5 mg / 100 ml - zoledronic acid - zoledronic acid - treatment of paget's disease of the bone. treatment of osteoporosis : - in post-menopausal women - in men at increased risk of fracture including those with a recent low-trauma hip fracture.treatment and prevention of glucocorticoid-induced osteoporosis.prevention of postmenopausal osteoporosis in women for whom bisphosphonate therapy is indicated.

ישראל - עברית - Ministry of Health

kamada ltd, israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg/ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - pregnancy/other obstetric conditions, suppression of rh immunization in non-sensitized rh0 (d) negative women delivering an rh0 positive baby or when the baby's rh type is unknown. suppression of rh immunization after spontaneous or induced abortions threatened abortion associated with maternal bleeding amniocentesis chorionic villus sampling ruptured tubal pregnancy and significant abdominal trauma. kam rh0 -d im should be given within 72 hours of the event. it may be given even after up to one month although efficacy may be somewhat reduced.transfusion: suppression of rh isoimmunization in rh0 (d) antigen-negative patients transfused with rh0 (d) antigen-positive rbcs of blood components containing rh0 (d) antigen-positive rbcs . initate treatment within 72 hours of exposure.

ישראל - עברית - Ministry of Health

kamada ltd, israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg / 1 ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - suppression of rh immunization in non-sensitized rho(d) negative women delivering an rh positive baby, or when the baby's rh type is unknown. suppression of rh immunization after spontaneous or induced abortions, threatened abortion associated with maternal bleeding amniocentesis, chorionic villus sampling ruptured tubal pregnancy, and significant abdominal trauma. kam-rho should be given within 72 hours of event. immune thrombocytopenic purpura (itp): rho (d)-positive adults with chronic itp, children with chronic or acute itp, and patients with thrombocytopenia secondary to hiv infection in clinical situations requiring an increase in platelet count to prevent excessive hemorrhage.

ישראל - עברית - Ministry of Health

cts chemical industries ltd, israel - ferrous as iron iii hydroxide polymaltose compl.; folic acid - טבליה - folic acid 0.4 mg; ferrous as iron iii hydroxide polymaltose compl. 100 mg - ferrous amino acid complex - ferrous amino acid complex - prevention and treatment of anemia caused by iron and folic acid deficiency including anemia of pregnancy and lactation.

ישראל - עברית - Ministry of Health

rekah pharmaceutical industry ltd, israel - folic acid - טבליה - folic acid 10 mg - folic acid - folic acid - treatment of folic acid deficiency megaloblastic anemia in malabsorption states.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - אבקה להכנת תרחיף - amoxicillin as trihydrate 50 mg/ml; clavulanic acid as potassium salt 12.5 mg/ml - ampicillin and enzyme inhibitor - ampicillin and enzyme inhibitor - for the treatment of lower respiratory tract infections, otitis media infections, sinusitis infections, acute pharyngitis, skin and soft tissues infections and urinary tract infections caused by beta-lactamase producing organisms which are susceptible to augmentin and are resistant to other beta-lactam antibiotics.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - טבליות מצופות פילם - amoxicillin as trihydrate 250 mg; clavulanic acid as potassium salt 125 mg - amoxicillin and enzyme inhibitor - amoxicillin and enzyme inhibitor - for the treatment of lower respiratory tract infections, otitis media infections, sinusitis infections, acute pharyngitis, skin and soft tissues infections and urinary tract infections caused also by beta-lactamase producing organisms witch are susceptible to augmentin and are resistant to other beta-lactam antibiotics.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - amoxicillin as trihydrate; clavulanic acid as potassium salt - טבליות מצופות פילם - amoxicillin as trihydrate 500 mg; clavulanic acid as potassium salt 125 mg - amoxicillin and enzyme inhibitor - amoxicillin and enzyme inhibitor - for the treatment of lower respiratory tract infections, otitis media infections, sinusitis infections, acute pharyngitis, skin and soft tissues infections and urinary tract infections caused by beta-lactamase producing organisms which are susceptible to augmentin and are resistant to other beta-lactam antibiotics.